Literature DB >> 15528134

Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation.

Loredana Ruggeri1, Marusca Capanni, Antonella Mancusi, Elena Urbani, Katia Perruccio, Emanuela Burchielli, Antonella Tosti, Fabiana Topini, Franco Aversa, Massimo F Martelli, Andrea Velardi.   

Abstract

Natural killer (NK) cell-mediated, donor-vs.-recipient alloresponses occur following transplantation of human leukocyte antigen (HLA) haplotype-mismatched hematopoietic stem cells (HSCs). NK cell alloreactivity reduced the risk of relapse in acute myeloid leukemia patients while improving engraftment and protecting against graft-vs.-host disease (GvHD). NK cells are primed to kill by several activating receptors. NK killing of autologous cells is prevented because NK cells co-express inhibitory receptors (killer cell Ig-like receptors, KIR) that recognize groups of (self) MHC class I alleles. As KIRs are clonally distributed, the NK population in any individual is constituted of a repertoire with different allospecificities. NK cells in the repertoire mediate alloreactions when the allogeneic targets do not express class I alleles that block them. High resolution molecular HLA typing of recipient and donor, positive identification of donor KIR genes, and in some cases, functional assessment of donor NK clones will identify haploidentical donors who are able to mount donor-vs.-recipient NK alloreactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528134     DOI: 10.1016/j.bcmd.2004.08.005

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  12 in total

Review 1.  Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.

Authors:  Nina Shah; Katy Rezvani; Chitra Hosing; Partow Kebriaei; William Wierda; Laurence Cooper; Elizabeth Shpall
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-09

2.  Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Authors:  Heather J Symons; M Sue Leffell; Nancy D Rossiter; Marianna Zahurak; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

3.  The diversity of KIR gene in Chinese Northern Han population and the impact of donor KIR and patient HLA genotypes on outcome following HLA-identical sibling allogeneic hematopoietic stem cell transplantation for hematological malignancy in Chinese people.

Authors:  Li Ping Dou; De Hua Zheng; Chang Wang; Jun Hua Liu; Jing Fen Sun; Hai Jie Jin; Chun Ji Gao; Li Yu; Wan Ming Da
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

4.  Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor.

Authors:  Martin Stern; Loredana Ruggeri; Antonella Mancusi; Maria Ester Bernardo; Claudia de Angelis; Christoph Bucher; Franco Locatelli; Franco Aversa; Andrea Velardi
Journal:  Blood       Date:  2008-05-20       Impact factor: 22.113

5.  Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.

Authors:  Firoozeh Sahebi; Laurent Garderet; Abraham S Kanate; Diderik-Jan Eikema; Nina Simone Knelange; Omar F Dávila Alvelo; Yener Koc; Didier Blaise; Qaiser Bashir; José M Moraleda; Peter Dreger; James F Sanchez; Stefan Ciurea; Harry Schouten; Nirav N Shah; Mareike Verbeek; Wolf Rösler; Jose L Diez-Martin; Stefan Schoenland; Anita D'Souza; Nicolaus Kröger; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-20       Impact factor: 5.742

6.  Selective expansion of human natural killer cells leads to enhanced alloreactivity.

Authors:  Diana N Eissens; Clive M Michelo; Frank W M B Preijers; Bram van Cranenbroek; Kjeld van Houwelingen; Arnold van der Meer; Irma Joosten
Journal:  Cell Mol Immunol       Date:  2013-11-18       Impact factor: 11.530

7.  Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.

Authors:  Nina Shah; Beatriz Martin-Antonio; Hong Yang; Stephanie Ku; Dean A Lee; Laurence J N Cooper; William K Decker; Sufang Li; Simon N Robinson; Takuya Sekine; Simrit Parmar; John Gribben; Michael Wang; Katy Rezvani; Eric Yvon; Amer Najjar; Jared Burks; Indreshpal Kaur; Richard E Champlin; Catherine M Bollard; Elizabeth J Shpall
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

Review 8.  Deciphering the Immunological Phenomenon of Adaptive Natural Killer (NK) Cells and Cytomegalovirus (CMV).

Authors:  Samantha Barnes; Ophelia Schilizzi; Katherine M Audsley; Hannah V Newnes; Bree Foley
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

9.  Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission.

Authors:  J Tanaka; Y Morishima; Y Takahashi; T Yabe; K Oba; S Takahashi; S Taniguchi; H Ogawa; Y Onishi; K Miyamura; H Kanamori; N Aotsuka; K Kato; S Kato; Y Atsuta; Y Kanda
Journal:  Blood Cancer J       Date:  2013-11-29       Impact factor: 11.037

10.  KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia.

Authors:  R Willemze; C A Rodrigues; M Labopin; G Sanz; G Michel; G Socié; B Rio; A Sirvent; M Renaud; L Madero; M Mohty; C Ferra; F Garnier; P Loiseau; J Garcia; L Lecchi; G Kögler; Y Beguin; C Navarrete; T Devos; I Ionescu; K Boudjedir; A-L Herr; E Gluckman; V Rocha
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.